Results of the Hercules Study: Economic Evaluation of the Healthcare Resources Utilization and Description of the Patient with Severe Uncontrolled Asthma in Italy Based on Real-World DATA
Author(s)
Colombo GL1, Di Matteo S2, Heffler E3, Puggioni F4, Martinotti C2, Kheiraoui F5, Boarino S5, Bruno G6
1Pavia University, Pavia, Italy, 2S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy, 3Humanitas University, Pieve Emanuele, Italy, 4Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy, 5AstraZeneca, Milan, Italy, 6Bergamo University, Milan, MI, Italy
OBJECTIVES: Severe asthma is a subtype of asthma that is difficult to treat and control. It affects 5-10% of patient with asthma and has an important burden on healthcare systems. The analysis of the disease through real-world data is a fundamental tool for knowing and managing these critical issues. METHODS: Based on national real-world data (SANI national registry, Severe Asthma Network in Italy), a cross-sectional observational study was developed to describe characteristics, treatment patterns, morbidity, co-morbidity, the healthcare resource utilization and costs of uncontrolled severe asthma patients in Italy. Data extracted were processed, analyzed and economically valued. Finally, the mean annual cost per patient, not including the therapies, and the mean cost per patient associated with treatments were obtained to estimate the economic impact of the disease on the NHS. RESULTS: The study included and analyzed data of 459 patients with severe uncontrolled asthma, according to the ERS/ATS classification. The main demographic and clinical characteristics of the population were described, and the economic impact of the disease were analyzed trough the valorization of the health care resources related to visits, diagnostic tests, comorbidities management, therapies and quality of life. The mean annual cost per patient, not including therapies, was estimated at € 5,331. Regarding the mean annual cost per patient of the therapies, it was equal to a maximum of respectively € 138 for rhinitis therapy, € 383 for oral therapy, €469 for inhalation therapy, €960 for immunotherapy, and €17.182 for monoclonal antibodies. CONCLUSIONS: This study provided real-world data about the patient with severe uncontrolled asthma in Italy, making possible clinical and economic assessments relating to the management of the disease.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PRS16
Topic
Clinical Outcomes, Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Clinician Reported Outcomes, Comparative Effectiveness or Efficacy, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders
Explore Related HEOR by Topic